August 30, 2023

First Ever Hemophilia Patient to Receive Gene Therapy Since FDA Approval



JUNE 20, 2023

GREEN BAY, WI- Wisconsin resident is the first ever hemophilia B patient to receive gene therapy since FDA approval.

“I feel honored to be the first person to participate in this therapy outside of the clinical trials. I am very excited that I am going to be helping to prove that this is a treatment option for individuals with hemophilia B.”-Mason Buxton

HEMGENIX (etranacogene dezaparvovec), manufactured by uniQure Inc. and distributed by CSL Behring LLC, was FDA approved November of 2022 and is for the treatment of adults with Hemophilia B (Factor IX Deficiency) who currently use Factor IX preventative therapy, or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes.

Hemophilia B is a genetic bleeding disorder resulting from missing or insufficient levels of blood clotting Factor IX, a protein needed to produce blood clots to stop bleeding. Symptoms can include prolonged or heavy bleeding after an injury, surgery, or dental procedure; in severe cases, bleeding episodes can occur spontaneously without a clear cause. Prolonged bleeding episodes can lead to serious complications, such as bleeding into joints, muscles or internal organs, including the brain. (Commissioner, O. of the (2022) FDA approves first gene therapy to treat adults with hemophilia B, U.S. Food and Drug Administration. Available at:,current%20or%20historical%20life%2Dthreatening (Accessed: 23 May 2023).

Although HEMGENIX is not a cure for Hemophilia B patients, the medical advancement may reduce, if not, eliminate weekly preventative factor replacement and bleeds.

“HEMGENIX is an important addition to the current treatment paradigm and a long-awaited advancement for the hemophilia B community,” said Matthew Ryan, MD, Adult Hematologist and Medical Director at Hemophilia Outreach Center, Green Bay, WI. “This exciting treatment offers patients a chance to live a life without frequent bleeds or the burden of regular infusions. The availability of this new one-time treatment also sparks additional conversations in the community when it comes to treatment options and goals, which is extremely important when managing a life-long condition, as an individual’s needs can change for a variety of reasons.”

“I’m just excited that patients have this new opportunity that will lead to such a better quality of life versus their current prophylaxis treatment! To live a life free from recurrent prophylaxis, not having that anxiety over if they are going to have a bleed or if they have factor with them, not worrying about damage to their joints from breakthrough bleeds….it will be very lifechanging for them.”- Andrea Miller, APNP, Hemophilia Outreach Center.

Recent Posts

Comprehensive Care at Hemophilia Treatment Centers

Hemophilia is a complex bleeding disorder requiring specialized management to maintain a high quality of life. Hemophilia treatment centers (HTCs) offer a multidisciplinary approach to care, designed to address the diverse needs of individuals living with hemophilia...

Advanced Treatments for Von Willebrand’s Disease

Understanding Von Willebrand Disease Von Willebrand Disease (vWD) is one of the most common hereditary bleeding disorders, affecting both men and women equally. It occurs due to a deficiency or dysfunction of von Willebrand factor (vWF), a protein crucial for blood...

Finding the Right Hemophilia Treatment Center Near You

For individuals and families navigating the complexities of hemophilia and other bleeding disorder diagnoses, finding a treatment center that offers comprehensive, personalized care is paramount. This in-depth guide aims to illuminate the path to finding the right...

Glanzmann Thrombasthenia: Understanding Your Treatment Options

Glanzmann Thrombasthenia is a rare bleeding disorder that necessitates a nuanced approach to care and management. This detailed guide not only elucidates treatment strategies but also underscores the significant support network available through the Hemophilia...

Introduction to “HHT Treatment: What You Need to Know”

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu disease, is a genetic disorder that affects blood vessels and can lead to significant health issues. Understanding the current treatments for HHT is crucial for those diagnosed with the...

Understanding and Managing Von Willebrand Disease

Von Willebrand Disease (VWD) is the most common hereditary bleeding disorder, affecting both men and women. Despite its prevalence, myths and uncertainties surround its management and impact on daily life. This comprehensive guide aims to demystify VWD, offering...

Navigating Medical Treatment for Hemophilia: A Comprehensive Guide

Hemophilia, a rare but significant bleeding disorder, requires nuanced understanding and specialized care. This guide, leveraging insights from the Hemophilia Outreach Center (HOC) and current medical institutions, offers a deep dive into managing hemophilia...

Aging and Bleeding Disorders

As our bleeding disorder population’s life expectancy continues to rise to that of the average American, our patients need to understand that they are at risk for the same disease states that over 50% of all Americans now...

Social Media